Printer friendly

What does CIC stand for?

CIC stands for Ciclesonide

This definition appears frequently and is found in the following Acronym Finder categories:

  • Science, medicine, engineering, etc.

See other definitions of CIC

Other Resources:
We have 692 other meanings of CIC in our Acronym Attic

Samples in periodicals archive:

Formulated as a pro-drug and in a unique hypotonic formulation, Omnaris[R] addresses some important improvements on allergic rhinitis treatments such as: drug activation on the target cells, fast onset of action (studies have shown onset of action within 1 to 6 hours), increased absorption of ciclesonide and longer retention in the nasal mucosa compared to isotonic formulations, low systemic availability (1 percent) and low spray volume leading to a safety and tolerability profile compared to placebo, convenience of once daily dosage and efficacy in all main allergic rhinitis symptoms (runny nose, itchy nose, sneezing and nasal congestion).
Currently marketed products include LUNESTA brand eszopiclone, XOPENEX brand levalbuterol HCl Inhalation Solution, XOPENEX HFA brand levalbuterol tartrate Inhalation Aerosol, BROVANA brand arformoterol tartrate Inhalation Solution, OMNARIS brand ciclesonide Nasal Spray and ALVESCO brand ciclesonide HFA Inhalation Aerosol.
Poster Presentations by Sunovion at AAAAI: * A Post-hoc Analysis of Improvement in Individual Nasal Symptoms by Their Baseline Severity Following Treatment with Ciclesonide Hydrofluoroalkane Nasal Aerosol in Patients with Seasonal Allergic Rhinitis (Poster #668) In two randomized, double-blind, placebo-controlled Phase III SAR studies that enrolled 918 patients 12 to 65 years of age with a 2 year history of SAR, patients were given ZETONNA 74 mcg [CIC-HFA (37 mcg/actuation nostril)] or placebo, once daily for two weeks.
and Nycomed announced an exclusive development, marketing and commercialization agreement for ciclesonide in the United States.
MUNICH, Germany, September 4 /PRNewswire/ -- - Lower dose of ciclesonide effectively controls asthma symptoms and maintains lung function New efficacy data was presented for the first time at the 16th Annual European Respiratory Society (ERS) Congress confirming that a lower dose, or "stepping-down" to ciclesonide (Alvesco(R)), a once-daily, novel, inhaled corticosteroid (ICS) therapy for the treatment of asthma, is an equally effective maintenance treatment as twice-daily fluticasone propionate, another available asthma therapy.